scholarly journals Increased Level of Serum Ceramides Correlate with Liver Steatosis, Hba1c and Cholesterol in Obese Patients

2020 ◽  
Vol 4 (1) ◽  
Keyword(s):  
Metabolic Syndrome ◽  
Metabolic Diseases ◽  
Glycosylated Hemoglobin ◽  
Liver Steatosis ◽  
Metabolic Parameters ◽  
Control Group ◽  
Obese Patients ◽  
Active Components ◽  
Cross Sectional ◽  
Nonalcoholic Fatty Liver

Objective: Sphingolipids including ceramides are biological active components of all cell membranes. They play a great role in cell interconnections in the process of proliferation, maturation, cell apoptosis and any fluctuations of their level can lead to development of metabolic diseases such as type 2 diabetes (T2D) and nonalcoholic fatty liver disease. Nevertheless, there is lack of information about what type of ceramides play a role in aforementioned diseases. Here we investigated the relationship between the serum level of some type of ceramides and parameters of metabolic syndrome that is commonly present in obese patients. Design: We performed cross-sectional study in two groups. One of them was control group – lean healthy people (n=10, body mass index, BMI 21, 2±1, 89) and the second group included patients with the obesity (n=24, BMI 33, 9±3, 1). We quantified the levels of serum ceramide by liquid chromatography-mass spectrometry, analyzed the parameters for insulin resistance, liver function and lipid metabolism by biochemical blood test. Results: The subjects with obesity had elevated level of ceramide C16:0, C18:0, C24:0 comparing with control group (p<0,001). As results of our study, we found correlation of the level ceramide C16:0, C18:0, C24:0 with the results of steatometry and some metabolic parameters (glycosylated hemoglobin (Hb A1C), cholesterol). Conclusion: These results demonstrate that obese subjects had increased level of ceramide C16:0, C18:0, C24:0 that correlated with some metabolic parameters supposedly recognizing them as new biomarkers of metabolic syndrome.

scholarly journals Increased Level of Serum Ceramides Correlate with Liver Steatosis, Hba1c and Cholesterol in Obese Patients

2020 ◽  
Vol 4 (1) ◽  
Keyword(s):  
Metabolic Syndrome ◽  
Metabolic Diseases ◽  
Glycosylated Hemoglobin ◽  
Liver Steatosis ◽  
Metabolic Parameters ◽  
Control Group ◽  
Obese Patients ◽  
Active Components ◽  
Cross Sectional ◽  
Nonalcoholic Fatty Liver

Objective: Sphingolipids including ceramides are biological active components of all cell membranes. They play a great role in cell interconnections in the process of proliferation, maturation, cell apoptosis and any fluctuations of their level can lead to development of metabolic diseases such as type 2 diabetes (T2D) and nonalcoholic fatty liver disease. Nevertheless, there is lack of information about what type of ceramides play a role in aforementioned diseases. Here we investigated the relationship between the serum level of some type of ceramides and parameters of metabolic syndrome that is commonly present in obese patients. Design: We performed cross-sectional study in two groups. One of them was control group – lean healthy people (n=10, body mass index, BMI 21, 2±1, 89) and the second group included patients with the obesity (n=24, BMI 33, 9±3, 1). We quantified the levels of serum ceramide by liquid chromatography-mass spectrometry, analyzed the parameters for insulin resistance, liver function and lipid metabolism by biochemical blood test. Results: The subjects with obesity had elevated level of ceramide C16:0, C18:0, C24:0 comparing with control group (p<0,001). As results of our study, we found correlation of the level ceramide C16:0, C18:0, C24:0 with the results of steatometry and some metabolic parameters (glycosylated hemoglobin (Hb A1C), cholesterol). Conclusion: These results demonstrate that obese subjects had increased level of ceramide C16:0, C18:0, C24:0 that correlated with some metabolic parameters supposedly recognizing them as new biomarkers of metabolic syndrome.

scholarly journals Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome

2020 ◽  
Vol 2020 ◽  
pp. 1-7 ◽  
Author(s):  
Hande Erman ◽  
Engin Beydogan ◽  
Seher Irem Cetin ◽  
Banu Boyuk
Keyword(s):  
Metabolic Syndrome ◽  
Fatty Liver ◽  
Liver Steatosis ◽  
Cutoff Point ◽  
Healthy Controls ◽  
Roc Curve Analysis ◽  
Cross Sectional ◽  
Nonalcoholic Fatty Liver ◽  
Fatty Liver Index ◽  
Hepatic Steatosis Index

Background. Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, which has recently been mentioned as an independent cardiovascular risk factor. Objectives. Endocan is a novel molecule of endothelial dysfunction. We aimed to evaluate the associations of serum endocan levels with the hepatic steatosis index (HSI), fatty liver index (FLI), and degrees of hepatosteatosis in patients with metabolic syndrome with NAFLD. Design and Setting. This cross-sectional prospective study was performed in the outpatient clinic of an internal medicine department. Methods. The study included 40 patients with metabolic syndrome with NAFLD as noted using hepatic ultrasound and 20 healthy controls. Secondary causes of fatty liver were excluded. FLI and HSI calculations were recorded. Serum endocan level values were obtained after overnight fasting. Results. Higher values of HSI and FLI were found in the NAFLD groups than in the control groups (p<0.001). Five (12.5%) of 20 patients with liver steatosis had grade 1 liver steatosis, 15 (37.5%) patients had grade 2 liver steatosis, and 20 (50%) patients had grade 3 liver steatosis. Serum endocan levels were lower in patients with NAFLD compared with the healthy controls (146.56±133.29 pg/mL vs. 433.71±298.01 pg/mL, p<0.001). ROC curve analysis suggested that the optimum endocan value cutoff point for NAFLD was 122.583 pg/mL (sensitivity: 71.79%, specificity: 90%, PPV: 93.3%, and NPV: 62.1%). Conclusion. Serum endocan concentrations are low in patients with NAFLD, and the optimum cutoff point is 122.583 pg/mL. HSI and FLI were higher in patients with NAFLD; however, there was no correlation with serum endocan.

Cut off value of plasma 25-hydroxyvitamin D concentration for predicting metabolic syndrome

2019 ◽  
pp. 68-73
Author(s):  
Trong Nghia Nguyen ◽  
Thi Nhan Nguyen ◽  
Thi Dua Dao
Keyword(s):  
Metabolic Syndrome ◽  
Medical Center ◽  
Cross Sectional Study ◽  
Control Group ◽  
Cross Sectional ◽  
Hydroxyvitamin D ◽  
The Metabolic Syndrome ◽  
25 Hydroxyvitamin D ◽  
Key Words Metabolic Syndrome ◽  
And Control

Background: The metabolic syndrome is a constellation of cardiometabolic risk factors that tend to cluster together in affected individuals more often than predicted by chance. The presence of the metabolic syndrome substantially increases the risk of developing type 2 diabetes and cardiovascular disease, and is associated with a range of adverse clinical outcomes, many of which are closely associated with aging. Current estimates suggest that approximately 20 - 25% of the world’s population is affected by the metabolic syndrome. The prevalence of the metabolic syndrome rises with age and more than 45% of people aged over 60 years have the metabolic syndrome. Recent studies show that low vitamin D status is very common in the world and this is a risk factor of metabolic syndrome. Objective: (1) Plasma 25-hydroxyvitamin D concentration in subjects with metabolic syndrome. (2) Cut off value of plasma 25-hydroxyvitamin D concentration for predicting metabolic syndrome. Material and method: A cross-sectional study with control group on 318 adult subjects for health examinations at International Medical Center at Hue Central Hospital, including 139 subjects with metabolic syndrome and control group of 179 healthy subjects. Metabolic syndrome was defined according to the IDF, NHLBI, AHA, WHF, IAS, IASO (2009). Plasma hydroxyvitamin D concentration was measured using chemiluminescent microparticle immunoassay. Reciever operating characteristic (ROC) curve were generated to assess sensitivity and specificity for different cut off value of 25-hydroxyvitamin D concentration for predicting metabolic syndrome. Results: Plasma 25-hydroxyvitamin D concentration in subjects with metabolic syndrome was 26.4 ng/ml, incidence of plasma 25-hydroxyvitamin D deficiency (59.7%) was significantly higher than in control group (23.5%) (p < 0.001). The optimal cut off point for 25-OH-D concentration for predictor of metabolic syndrome as 26.4 ng/ml (AUC=0.657, sensitivity=53.4%, specificity=71.6%). Conclusion: In 139 subjects with metabolic syndrome, the plasma 25-hydroxyvitamin D concentration was 26.4 ng/ml and the incidence of 25-hydroxyvitamin D deficiency in the metabolic syndrome group was 59.7%. The optimal cut off point for plasma 25-hydroxyvitamin D concentration for predictor of metabolic syndrome as 26.4 ng/ml. Key words: Metabolic syndrome, 25-hydroxyvitamin D

Association between the FINDRISC score and the risk of metabolic syndrome and hepatic steatosis

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
D Godoi Bernardes Da Silva ◽  
R Dias Santos ◽  
M Sommer Bittencourt ◽  
J.A.M Carvalho ◽  
M Franken ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Hepatic Steatosis ◽  
Longitudinal Analysis ◽  
Metabolic Diseases ◽  
Low Cost ◽  
Cross Sectional ◽  
Predictive Values ◽  
Cross Sectional Analysis ◽  
The Cross ◽  
Sectional Analysis

Abstract Introduction The Finnish Diabetes Risk Score (FINDRISC) was developed in Europe to predict type 2 diabetes mellitus (T2DM) risk without need of laboratory tests. Small cross-sectional studies analyzed the association between RF with metabolic syndrome (MS) or hepatic steatosis (HS). Our objective was to test the association of FINDRISC with MS or HS, in a transversal and longitudinal way. Methods In 41,668 individuals (age 41.9±9.7 years; 30.8% women) who underwent health evaluation between 2008 and 2016 in a single centre in Brazil, we tested the transversal association between FINDRISC and MS or HS, in multivariate models. The same analyzes were performed longitudinally in non-diabetic subgroups, followed for 5±3 years, to test the predictive value of FINDRISC and the incidental risk of MS (n=10,075 individuals) or HS (n=7,097 individuals), using logistic regression. Models were adjusted for confounders such as sex, use of medications for dyslipidemia, smoking, and baseline plasma levels of glucose, creatinine and lipids. A receiver operating characteristic (ROC) curve was used to evaluate the discriminative and predictive values of FINDRISC for MS and HS. Results In the cross-sectional analysis, 2,252 (5%) individuals had MS and 14,176 (34%) HS. In the longitudinal analysis, there were 302 cases of incidental MS (2%) and 1,096 cases of HS (15%). FINDRISC was independently associated with MS and HS in the cross-sectional analysis (respectively, OR 1.27, 95% CI: 1.25–1.28, P&lt;0.001; and OR 1.21, 95% CI: 1.20–1.22, P&lt;0.001, per FINDRISC unit) and in longitudinal analysis (respectively, OR of 1.18, 95% CI: 1.15–1.21, P&lt;0.001; and OR of 1.10, 95% CI: 1.08–1.11, P&lt;0.001, per FINDRISC unit). In comparison with individuals with low FINDRISC, those with moderate, high and very high values showed significant and proportional increases of the 12 to 77 fold in the chance of current SM (P&lt;0.001) and 3 to 10 fold in the chance of HS (P&lt;0.001). During follow-up, these increases were 3 to 10 fold in the chance of incidental MS (P&lt;0.001) and 1 to 3 fold in the chance of HS (P&lt;0.001). The AUC from cross-sectional analysis for MS and HS were respectively 0.82 (95% CI 0.81–0.83) and 0.76 (95% CI 0.75–0.76), and in longitudinal analysis 0.73 (95% CI 0.70–0.76) and 0.63 (95% CI 0.61–0.65), respectively. Conclusion FINDRISC was associated with the presence and onset of MS and HS, but it predicted better metabolic syndrome risk than hepatic steatosis. Therefore, this simple, practical and low-cost score can be useful for population screening and identification of subgroups of individuals at higher risk future metabolic diseases. Funding Acknowledgement Type of funding source: None

The analysis of surface saccharide profiles through fluorescein-labelled lectins in a rat pancreatic tissue with established metabolic syndrome model

2018 ◽  
Vol 44 (1) ◽  
pp. 98-104
Author(s):  
Yosun Mater ◽  
Sule Beyhan-Ozdas
Keyword(s):  
Metabolic Syndrome ◽  
Metabolic Diseases ◽  
Pancreatic Tissue ◽  
Control Group ◽  
High Fructose Diet ◽  
Tissue Sections ◽  
Membrane Surfaces ◽  
High Fructose ◽  
A Cell ◽  
And Control

Abstract“Glycans”, which are generally referred as oligosaccharides and polysaccharides, are structures that are present on all cellular surfaces with proteins and lipids being attached to their basic chain structures. Many studies in the field of glycobiology have identified the various and complicated biological roles of these glycans which make them perfect molecules to use in labelling and selecting body cells specifically. This study aims at analyzing the modifications in saccharide units of glycans on a cell membrane surfaces of the pancreatic tissue of rats to which normal and metabolic syndrome (MetS) are established. To this end, a MetS model was created through a high fructose diet in Spraque Dawley breed of rats and the pancreatic tissue sections of the group with MetS and control group animals were evaluated comparatively. The targeted saccharide units were examined with Fluorescent Microscope by using two different Fluorescein (FITC) labelled lectins, namely Maackia amurensis-1 lectin [FITC-(MAL-I)] and the Wheat Germ Agglutinin (FITC-WGA). It was observed that FITC-MAL-1-labelled Galβ4GlcNAc units did not change much due to high- fructose diet. On the other hand, more GlcNAc, Neu5Ac and β-GlcNAc units which are labelled with FITC-WGA lectin increase in numbers in pancreatic sections of high fructose diet, compared to control group. Thus, a rapid and specific labelling method, which can identify surface saccharide sequences specifically, was developed. The method can be used in early diagnosis and/or treatment for metabolic diseases.

Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: A cross-sectional study

2018 ◽  
Vol 37 (5) ◽  
pp. 1550-1557 ◽  
Author(s):  
Joo Hee Kwak ◽  
Dae Won Jun ◽  
Seung Min Lee ◽  
Yong Kyun Cho ◽  
Kang Nyeong Lee ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Cross Sectional Study ◽  
Obese Patients ◽  
Sectional Study ◽  
Cross Sectional ◽  
Nonalcoholic Fatty Liver

scholarly journals Sex Differences in Rest-Activity Circadian Rhythm in Patients With Metabolic Syndrome

2021 ◽  
Vol 12 ◽  
Author(s):  
Antonino Mulè ◽  
Eleonora Bruno ◽  
Patrizia Pasanisi ◽  
Letizia Galasso ◽  
Lucia Castelli ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Circadian Rhythm ◽  
Metabolic Diseases ◽  
Activity Level ◽  
Activity Count ◽  
Cross Sectional ◽  
The Metabolic Syndrome ◽  
Parametric Analyses ◽  
Rest Activity

Rest-Activity circadian Rhythm (RAR) can be used as a marker of the circadian timing system. Recent studies investigated the relationship between irregular circadian rhythms and cardiovascular risk factors such as hypertension, obesity, and dyslipidemia. These factors are related to the Metabolic Syndrome (MS), a clustering of metabolic risk factors that increases the risk of several cardiovascular and metabolic diseases. This cross-sectional analysis aimed to explore the RAR characteristics by actigraphy in subjects with MS, particularly in relation to sex and MS parameters, using parametric and non-parametric analyses. Distinguishing the characteristics of RAR based on sex could prove useful as a tool to improve the daily level of activity and set up customized activity programs based on each person’s circadian activity profile. This study showed that female participants exhibited higher values than male participants in the Midline Estimating Statistic of Rhythm (MESOR) (243.3 ± 20.0 vs 197.6 ± 17.9 activity count), Amplitude (184.5 ± 18.5 vs 144.2 ± 17.2 activity count), which measures half of the extent of the rhythmic variation in a cycle, and the most active 10-h period (M10) (379.08 ± 16.43 vs 295.13 ± 12.88 activity count). All these parameters are indicative of a higher daily activity level in women. Female participants also had lower Intradaily Variability (IV) than male participants (0.75 ± 0.03 vs 0.85 ± 0.03 activity count), which indicates a more stable and less fragmented RAR. These preliminary data provide the first experimental evidence of a difference in RAR parameters between male and female people with MS.

scholarly journals Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups

2018 ◽  
Vol 46 (11) ◽  
pp. 4447-4454 ◽  
Author(s):  
Ajit Ramakant Mahale ◽  
Sonali Dattatray Prabhu ◽  
Muthiah Nachiappan ◽  
Merwyn Fernandes ◽  
Sonali Ullal
Keyword(s):  
Metabolic Syndrome ◽  
Early Detection ◽  
Fatty Liver ◽  
Clinical Relevance ◽  
Glycosylated Hemoglobin ◽  
Lipoprotein Metabolism ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Asymptomatic Patients

Objective Ultrasonography is an efficient technique for detecting fatty liver. Its sensitivity and specificity in detecting moderate to severe fatty liver are comparable to those of histology. Fatty liver is associated with abnormal lipid and lipoprotein metabolism and insulin resistance, metabolic syndrome, cardiovascular/renal disease, type 2 diabetes, and other conditions. This study was performed to compare the serum lipid profiles and serum glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), and glycosylated hemoglobin (HbA1c) levels in patients diagnosed with fatty liver on ultrasonography versus controls without fatty liver and evaluate the clinical relevance of an ultrasound diagnosis of fatty liver in routine health checkups. Methods This hospital-based cross-sectional study included 390 patients who underwent health checkups; 226 were diagnosed with fatty liver (cases) and 164 were not (controls). The lipid profile, serum GOT and GPT levels, and HbA1c level were compared between the cases and controls. Results The cases had considerably higher levels of lipids, liver enzymes (serum GOT and GPT), and HbA1c than controls. Conclusion Ultrasonography is a noninvasive simple tool for early detection of fatty liver in asymptomatic patients and can help clinicians achieve early detection of metabolic syndrome.

scholarly journals Platelet Counts and Liver Enzymes after Bariatric Surgery

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Hans-Erik Johansson ◽  
Arvo Haenni ◽  
Björn Zethelius
Keyword(s):  
Liver Enzymes ◽  
Liver Steatosis ◽  
Fat Content ◽  
Liver Fat ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Liver Fat Content ◽  
Nonalcoholic Fatty Liver ◽  
Platelet Counts ◽  
Inflammatory Conditions

Background. Obesity is characterized by liver steatosis, chronic inflammation, and increased liver enzymes, that is, gamma-glutamyltransferase (GGT) and alanine aminotransferase (ALT), markers for nonalcoholic fatty liver disease (NAFLD) and liver fat content. Increased platelet counts (PCs) are associated with inflammatory conditions and are a valuable biomarker of the degree of fibrosis in NAFLD. We investigated alterations in PC, GGT, and ALT after biliopancreatic diversion with duodenal switch (BPD-DS) and Roux-en-Y gastric bypass (RYGBP).Methods. Ten morbidly obese patients (body mass index, BMI:53.5±3.8 kg/m2) who underwent BPD-DS were evaluated preoperatively (baseline) and 1 year (1st followup) and 3 years (2nd followup) after surgery and compared with 21 morbidly obese patients (BMI:42.3±5.2 kg/m2) who underwent RYGBP.Results. Over the 3 years of followup, changes in BPD-DS and RYGBP patients (BPD-DS/RYGBP) were as follows: BMI (−44%/−24%), GGT (−63%/−52%), and ALT (−48%/−62%). PC decreased (−21%) statistically significantly only in BPD-DS patients.Conclusions. Morbidly obese patients treated by RYGBP or BPD-DS show sustained reductions in BMI, ALT, and GGT. The decrease in PC and liver enzymes after BPD-DS may reflect a more pronounced decrease of liver-fat-content-related inflammation and, as a result, a lowered secondary thrombocytosis.

scholarly journals Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

2017 ◽  
Author(s):  
Junli Ma ◽  
Qihang Zhou ◽  
Houkai Li
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Targeted Therapies ◽  
Fatty Liver Disease ◽  
Metabolic Diseases ◽  
Herbal Medicines ◽  
Active Components ◽  
Nonalcoholic Fatty Liver

Gut microbiota play critical roles in development of obese-related metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, and insulin resistance, which highlighted the potential of gut microbiota-targeted therapies on these diseases. There are various ways that can manipulate gut microbiota including probiotics, prebiotics, synbiotics, antibiotics and some active components from herbal medicines. In this review, we first reviewed the main roles of gut microbiota in mediating the development of NAFLD, and the advances in gut microbiota-targeted therapies on NAFLD in both the experimental and clinical studies, as well as the conclusions on the prospect of gut microbiota-targeted therapies in the future.

Sign in / Sign up

Export Citation Format

Share Document